Create a narrative

Phathom Pharmaceuticals Community

NasdaqGS:PHAT Community

1 Narratives written by author
0 Comments on narratives written by author
4 Fair Values set on narratives written by author

Create a narrative

Phathom Pharmaceuticals

AN

AnalystConsensusTarget

Consensus Narrative from 8 Analysts

Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity

Key Takeaways Phathom focuses on VOQUEZNA's market potential in GERD treatment to drive substantial revenue while aiming for profitability through strategic cost management. New strategies and leadership in sales and marketing are set to optimize operations, potentially extending VOQUEZNA's market exclusivity and enhancing financial performance.

US$17.63

FV

76.8% undervalued

92.76%

Revenue growth p.a.

0

0

0

8 days ago